Current Cancer Drug Targets

Editor-in-Chief

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)

Personal Subscription
Become EABM
Become Reviewer

Cancer Therapy Through Control of Cell Migration

Volume:5   Issue: 7
Pp: 505-518
Eugene G. Levin
DOI: 10.2174/156800905774574048

Inhibition of Angiogenesis by Cleaved High Molecular Weight Kininogen (HKa) and HKa Domain 5

Volume:5   Issue: 7
Pp: 519-528
Keith R. McCrae, Fernando Donate, Sergei Merkulov, Danyu Sun, Xiaoping Qi and David E. Shaw
DOI: 10.2174/156800905774574039

Anti-Angiogenic and Anti-Tumor Properties of Proteasome Inhibitors

Volume:5   Issue: 7
Pp: 529-541
Kenyon G. Daniel, Deborah J. Kuhn, Aslamuzzaman Kazi and Q. P. Dou
DOI: 10.2174/156800905774574075

Control of Copper Status for Cancer Therapy

Volume:5   Issue: 7
Pp: 543-549
Vicki L. Goodman, George J. Brewer and Sofia D. Merajver
DOI: 10.2174/156800905774574066

Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose

Volume:5   Issue: 7
Pp: 551-559
Yuval Shaked, Guido Bocci, Raquel Munoz, Shan Man, John M.L. Ebos, Daniel J. Hicklin, Francesco Bertolini, Robert D'Amato and Robert S. Kerbel
DOI: 10.2174/156800905774574020